Citation: | Chinese Society of Liver Cancer, China Anti-Cancer Association, Chen Minshan. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition)[J]. Chinese Journal of Digestive Surgery, 2021, 20(7): 754-759. DOI: 10.3760/cma.j.cn115610-20210618-00288 |
Hepatocellular carcinoma (HCC) has a high incidence in China. Most of HCC patients are in the intermediate or advanced stages when diagnosed, with poor response to conventional therapies. Seeking new effective treatments and adopting reasonable multidisciplinary and comprehensive treatment strategies are key points to improve the prognosis of these patients. In recent years, domestic scholars have innovatively applied the oxaliplatin-based FOLFOX regimen to hepatic artery infusion chemotherapy (HAIC), which has significantly improved the tumor response rate and patient survival rate, and has received more and more attention and been more widely used. The Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition) is a collection of the experiences from Chinese experts in the field of HAIC for HCC, aiming to use it as a prototype to seek common ground while reserving differences, and to apply HAIC in the treatment of HCC in a more rational and effective way.
[1] |
郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19‑28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008.
|
[2] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J/CD].肿瘤综合治疗电子杂志,2020,6(2):55‑85. DOI: 10.12151/JMCM.2020.02-10.
|
[3] |
中国抗癌协会肝癌专业委员会.中国肝癌多学科综合治疗专家共识[J/CD].中国医学前沿杂志:电子版,2020,12(12):28‑36. DOI: 10.12037/YXQY.2020.12-06.
|
[4] |
LinCP, YuHC, ChengJS, et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5‑flourouracil for unresectable advan-ced hepatocellular carcinoma[J]. J Chin Med Assoc,2004, 67(12):602‑610.
|
[5] |
TsaiWL, LaiKH, LiangHL, et al. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepa-tocellular carcinoma[J]. PLoS One,2014,9(5):e92784. DOI: 10.1371/journal.pone.0092784.
|
[6] |
HeMK, LeY, LiQJ, et al. Hepatic artery infusion chemo-therapy using mFOLFOX versus transarterial chemoem-bolization for massive unresectable hepatocellular carci-noma: a prospective non‑randomized study[J]. Chin J Cancer,2017,36(1):83. DOI:10.1186/s40880- 017-0251-2.
|
[7] |
GourdK, LaiC, ReevesC. ESMO Virtual Congress 2020[J]. Lancet Oncol,2020,21(11):1403‑1404. DOI:10.1016/S14 70-2045(20)30585-4.
|
[8] |
KudoM, UeshimaK, YokosukaO, et al. Sorafenib plus low‑dose cisplatin and fluorouracil hepatic arterial infu-sion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a rando-mised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol,2018,3(6):424‑432. DOI: 10.1016/S2468-1253(18)30078-5.
|
[9] |
LyuN, LinY, KongY, et al. FOXAI: a phase Ⅱ trial evalua-ting the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut,2018,67(2):395‑396. DOI: 10.1136/gutjnl-2017-314138.
|
[10] |
HeM, LiQ, ZouR, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol,2019,5(7):953‑960. DOI: 10.1001/jamaoncol.2019.0250.
|
[11] |
LaiC. SSO 2020 virtual meeting[J]. Lancet Oncol,2020, 21(10):1263. DOI: 10.1016/S1470-2045(20)30522-2.
|
[12] |
ChoiJH, ChungWJ, BaeSH, et al. Randomized, prospec-tive, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol,2018,82(3):469‑478. DOI: 10.1007/s00280-018-3638-0.
|
[13] |
LyuN, KongY, MuL, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol,2018,69(1):60‑69. DOI: 10.1016/j.jhep.2018.02.008.
|
[14] |
IkedaM, ShimizuS, SatoT, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: rando-mized phase Ⅱ trial[J]. Ann Oncol,2016,27(11):2090-2096. DOI: 10.1093/annonc/mdw323.
|
[15] |
MaiQ. Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma[R/OL]. (2020-05-01)[2021-7-02]. https://meetinglibrary.asco.org/record/186697/abstract.
|
[16] |
MeiJ, LiSH, LiQJ, et al. Anti‑PD‑1 immunotherapy im-proves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma,2021,8:167‑176. DOI: 10.2147/JHC.S298538.
|
[17] |
XuLi.Hepatic arterial infusion chemotherapy in com-bination with PD-1 inhibitor as conversion therapy in locally advanced, potentially resectable hepatocellular carcinoma: a phase Ⅱ study. (2021-06-26)[ 2021-7-02]. https://easl.eu/event/the-international-liver-con gress-2021/submit-your-abstract/#ILC-2021-abstract-categories.
|
[18] |
MeiJ, TangYH, WeiW, et al. Hepatic arterial infusion chemotherapy combined with PD‑1 inhibitors plus lenvatinib versus PD‑1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J]. Front Oncol,2021, 11:618206. DOI: 10.3389/fonc.2021.618206.
|
[19] |
HeMK, LiangRB, ZhaoY, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol,2021,13:17588359211002720. DOI: 10.1177/17588359211002720.
|
[20] |
GuYK. Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: real-world data from a single center[R/OL]. (2020-05-01) [2021-7-02]. https://meetinglibrary.asco.org/record/186421/abstract.
|
[21] |
LiB, QiuJ, ZhengY, et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma[J]. Ann Surg,2021,2(2):e057.
|
[22] |
HamaokaM, KobayashiT, KurodaS, et al. Hepatectomy after down‑staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retro-spective cohort study[J]. Int J Surg,2017,44:223‑228. DOI: 10.1016/j.ijsu.2017.06.082.
|
[23] |
ChongJU, ChoiGH, HanDH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol,2018,25(11):3308‑3315. DOI: 10.1245/s10434-018-6653-9.
|
[24] |
LiSH. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: an interim analysis of a multi-center, phase 3, randomized, controlled clinical trial[R/OL]. (2021-06-01)[2021-7-02]. https://meetings.asco.org/abstracts-presen tations/197171.
|
[25] |
LiS, MeiJ, WangQ, et al. Postoperative adjuvant trans-arterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase Ⅲ, randomized controlled clinical trial[J]. Ann Surg Oncol,2020,27(13):5183‑5190. DOI: 10.1245/s10434-020-08601-8.
|
[1] | Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer, China Anti‐Cancer Association, Fan Jia. Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)[J]. Chinese Journal of Digestive Surgery, 2024, 23(4): 492-513. DOI: 10.3760/cma.j.cn115610-20240228-00135 |
[2] | Chinese Association of Liver Cancer of Chinese Medical Doctor Association, Li Qiu, Cheng Shuqun. Chinese expert consensus on the whole‑course management of hepatocellular carcinoma (2023 edition)[J]. Chinese Journal of Digestive Surgery, 2023, 22(7): 824-842. DOI: 10.3760/cma.j.cn115610-20230605-00261 |
[3] | The Chinese Chapter of the International Hepato-Pancreato-Biliary Association; Group of Liver Surgery, Surgical Society of Chinese Medical Association; Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology, Chen Xiaoping, Xia Feng. Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma (2023 version)[J]. Chinese Journal of Digestive Surgery, 2023, 22(3): 293-315. DOI: 10.3760/cma.j.cn115610-20230310-00103 |
[4] | The Chinese Chapter of International Hepato-Pancreato-Biliary Association, Chinese Society of Liver Cancer, Society for Hepato-pancreato-biliary Surgery of Chinese Research Hospital Association, Society for Virus and Tumor of Chinese Research Hospital Association, Chen Xiaoping, Fan Jia, Dong Jiahong, Li Xin, Chen Chengwei, Zhou Weiping. Chinese expert consensus on antiviral therapy for hepatitis B virus-related hepatocellular carcinoma (2023 edition)[J]. Chinese Journal of Digestive Surgery, 2023, 22(1): 29-41. DOI: 10.3760/cma.j.cn115610-20221024-00612 |
[5] | The Chinese Chapter of the International Hepato-Pancreato-Biliary Association; Group of Liver Surgery, Surgical Society of Chinese Medical Association; Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology, Chen Xiaoping, Xia Feng. Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma (2021 version)[J]. Chinese Journal of Digestive Surgery, 2021, 20(7): 740-753. DOI: 10.3760/cma.j.cn115610-20210603-00260 |
[6] | Fan Jia. Chinese expert consensus on conversion therapy in hepatocellular carcinoma (2021 edition)[J]. Chinese Journal of Digestive Surgery, 2021, 20(6): 600-616. DOI: 10.3760/cma.j.cn115610-20210512-00223 |
[7] | Chen Minshan, Hu Zili. Research progress of hepatic arterial infusion chemotherapy in the conversion therapy of hepatocellular carcinoma[J]. Chinese Journal of Digestive Surgery, 2021, 20(2): 171-177. DOI: 10.3760/cma.j.cn115610-20201230-00813 |
[8] | Chinese Research Hospital Association, Society for Hepato-pancreato-biliary Surgery. Chinese expert consensus on laparoscopic hepatectomy for hepatocellular carcinoma (2020 edtion)[J]. Chinese Journal of Digestive Surgery, 2020, 19(11): 1119-1134. DOI: 10.3760/cma.j.cn115610-20201029-00682 |
[9] | Chinese Research Hospital Association, Society for Hepatopancreatobiliary Surgery. Expert consensus on enhanced recovery after hepatopancreatobiliary surgery (2015 edition)[J]. Chinese Journal of Digestive Surgery, 2016, 15(1): 1-6. DOI: 10.3760/cma.j.issn.1673-9752.2016.01.001 |
[10] | Professional Committee of Minimally Invasive Surgeons, Surgeons Branch of Chinese Medical Doctor Association. Expert consensus on laparoscopic treatment of hepatolithiasis (2013 edition)[J]. Chinese Journal of Digestive Surgery, 2013, 12(1): 1-5. DOI: 10.3760/cma.j.issn.1673-9752.2013.01.001 |